MISDIAGNOSIS of demyelinating conditions remains an ongoing operational hurdle across modern neurological practice, leading to inappropriate exposure to disease-modifying therapies and unaddressed primary pathology. Comprehensive pooled data indicates that multiple sclerosis misdiagnosis occurs in approximately 15% of patients globally, with reported frequency ranges spanning between 5% and 41% depending on referral setting and clinical subspecialty. These errors contribute to prolonged physical distress and expose individuals to avoidable immunotherapy risks while true underlying disease processes remain untreated.
The systematic analysis highlighted substantial demographic disparity, revealing that female patients are more than twice as likely as male patients to receive an inaccurate label. Across the reviewed cohorts, diagnostic correction was delayed considerably, ranging from several months to as long as 15.9 years before a clinician revised the original impression. Non-specific presentations such as migraine with aura, fibromyalgia, metabolic disturbances, and functional neurological conditions were most commonly mistaken for classic demyelinating pathology.
Clinicians frequently over-rely on magnetic resonance imaging without properly contextualizing incidental T2-hyperintense white matter lesions. Nonspecific microvascular alterations and age-associated changes often mimic central nervous system demyelination on scans, yet lack true dissemination in time or space when cross-referenced against stringent criteria. Misinterpreting atypical sensory changes or subjective weakness further drives premature confirmation without adequate exclusion of alternative diagnoses.
Addressing multiple sclerosis misdiagnosis demands thorough adherence to established diagnostic frameworks and regular multi-disciplinary case re-evaluations whenever disease courses deviate from expectations. Objective biomarkers such as cerebrospinal fluid analysis for oligoclonal bands and targeted spinal axis neuroimaging remain essential components when clarifying ambiguous cerebral findings. Enhanced clinical discrimination ensures patients avoid unnecessary disease-modifying regimens while receiving timely, targeted interventions for their primary medical disorders.
Establishing dedicated secondary review pathways for ambiguous presentations offers an essential safeguard against long-term misclassification. Because disease-modifying therapies carry meaningful physical and psychological burdens, neurology teams must remain vigilant in distinguishing primary demyelination from vascular, metabolic, or functional mimics. Regular diagnostic audits and a willingness to reassess prior clinical conclusions ensure patients receive targeted care while sparing misidentified individuals the risks of prolonged immunosuppression.
Reference
Zürrer WE et al. Misdiagnosis and underdiagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 2024;30(11-12):1409–1422.
New Africa on Adobe stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
